TargetMol

SB 216763

Product Code:
 
TAR-T3077
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T3077-2mg2mg£97.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3077-1mL1 mL * 10 mM (in DMSO)£109.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3077-5mg5mg£109.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3077-10mg10mg£128.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3077-25mg25mg£177.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3077-50mg50mg£237.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3077-100mg100mg£352.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3077-500mg500mg£750.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
SB216763 is an effective and specific GSK-3α/β inhibitor (IC50: 34.3 nM).
CAS:
280744-09-4
Formula:
C19H12Cl2N2O2
Molecular Weight:
371.22
Pathway:
Stem Cells; PI3K/Akt/mTOR signaling; Autophagy
Purity:
0.9961
SMILES:
Cn1cc(C2=C(C(=O)NC2=O)c2ccc(Cl)cc2Cl)c2ccccc12
Target:
GSK-3; Autophagy

References

1. Coghlan MP, et al. Chem Biol, 2000, 7(10), 793-803. 2. Cross DA, et al. J Neurochem, 2001, 77(1), 94-102. 3. Ougolkov AV, et al. Cancer Res, 2005, 65(6), 2076-2081. 4. Gurrieri C, et al. J Pharmacol Exp Ther, 2010, 332(3), 785-794. 5. Ruan B, Liu W, Chen P, et al. NVP-BEZ235 inhibits thyroid cancer growth by p53-dependent/independent p21 upregulation[J]. International Journal of Biological Sciences. 2020, 16(4): 682.